BAP1 alterations stood out in kidney (9.9%) and cervix (2.9%) cancers, with ATM most frequent in bladder cancer (7.7%), CDK12 notable in prostate cancer (7.4%), and FANCA prominent in melanoma (3.1%). This evidence concerns the gene FANCA and prostate carcinoma.